This story was first published in digitalhealth.net
‘Costly’ breast cancer drug Kadcyla to now be offered on the NHS in England
A breast cancer drug which was repeatedly considered too costly to implement will now be offered on the NHS. It comes after a confidential deal between the health service and Roche, a drug company, was made.
The drug, which usually costs £90,000 per patient, adds an average of six months of life to women suffering with a form of terminal breast cancer.
The drug, which will benefit 1,200 women per year, has been called ‘monumental’ by campaigners.
Simon Stevens, NHS England chief executive, said: “Tough negotiation and flexibility between the NHS and Roche means both patients and taxpayers are getting a good deal.”
Richard Erwin, general manager at Roche, said: “Close collaboration between Roche, NHS England and NICE has resulted in NICE recommending Kadcyla as a cost-effective treatment. This is a positive example of how solutions can be reached when all parties show flexibility."
Latest News
16/02/2024 - 12:56
Hammersmith and Fulham Council has created a new alliance intended to clean dirty air and improve residents' health.
16/02/2024 - 10:44
Two million more GP appointments a month are being delivered for patients compared to the same month before the pandemic as part of the NHS primary care access recovery plan according to new NHS data.
15/02/2024 - 10:26
The Welsh Government has provided innovation funding of £380,000 to support two projects utilising technology in domiciliary care.
15/02/2024 - 10:13
The new Scottish health secretary has met with frontline staff at Queen Elizabeth University Hospital in Glasgow.
14/02/2024 - 10:27
The North East London NHS Foundation Trust (NELFT) has appointed three new Executive Directors to the Trust Board.
Product Features
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Supplier Profiles
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Latest Features
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly
